The aim of this study is to evaluate the effect of adding low-dose hCG to GnRH antagonist+r-hFSH protocole on the outcome of ART in the patients undergoing IVF/ICSI cycle. This study is a clinical trial. In all 120 patients pre-treatment with OCP will be given during the cycle prior to the IVF/ICSI. r-hFSH (150-300 IU) will be loaded on either day 2 or 3 of the menstural cycle, and the full dose will be continued until two follicles reach 14-15 mm in size, then daily administration of 0.25 mg of cetrorelix will be started. The starting dose of FSH will be chosen according to patient’s age, BMI, and ovarian responsiveness in previous cycle. according to the study group, patients will receive or will not, a daily injection of hCG (200 IU). when at least 2 follicles reach 18 mm in size, 10000 IU of hCG will be injected and oocyt retrieval will be performed within 35-36 hours. After that, All patients will undergo an ICSI procedure. Luteal phase will be started on the day of oocyt retrieval by vaginal administration of cyclogest 400 mg/day. BhCG will be checked 15 days after oocyte retrieval and pregnancy will be confirmed by pregnancy sac visualization by week 6. Serum E2 level on the day of hCG administration, number of total oocyts, number of mature oocyt, FSH total dose, duration of stimulation, number of good quality embryo, fertilization and pregnancy rate will be compared between two groups.